News & Updates

Show Multimedia Only
Data support abrocitinib use beyond 2 years in adolescents with AD

Data support abrocitinib use beyond 2 years in adolescents with AD

05 Nov 2024 byMike Ng

Treating adolescents with moderate-to-severe AD with the JAK1-selective inhibitor abrocitinib has demonstrated an acceptable long-term safety profile and maintained efficacy for up to 112 weeks, as shown in an adolescent-focused post hoc analysis of 5 phase III trials

Data support abrocitinib use beyond 2 years in adolescents with AD

05 Nov 2024
Opioid does little to ease pain in aSAH-related headache

Opioid does little to ease pain in aSAH-related headache

04 Nov 2024